Literature DB >> 9634791

A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic.

P P Ward1, C S Piddington, G A Cunningham, X Zhou, R D Wyatt, O M Conneely.   

Abstract

We previously reported the production of limited quantities of biologically active recombinant human lactoferrin in the filamentous fungus Aspergillus oryzae. In the present study, we report a modification of this production system combined with a classical strain improvement program that has enabled production of levels of recombinant human lactoferrin in excess of 2 g/l. The protein was expressed in Aspergillus awamori as a glucoamylase fusion polypeptide which was secreted into the growth medium and processed to mature human lactoferrin by an endogenous KEX-2 peptidase. The recombinant protein retains full biological activity in terms of its ability to bind iron and human enterocyte receptors. Furthermore, the recombinant protein functions as a potent broad spectrum antimicrobial protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9634791     DOI: 10.1038/nbt0595-498

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  27 in total

Review 1.  Filamentous fungi as production organisms for glycoproteins of bio-medical interest.

Authors:  M Maras; I van Die; R Contreras; C A van den Hondel
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

Review 2.  Structure and biological actions of lactoferrin.

Authors:  J H Nuijens; P H van Berkel; F L Schanbacher
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

3.  Extracellular proteome of Aspergillus terreus grown on different carbon sources.

Authors:  Mee-Jung Han; Nag-Jong Kim; Sang Yup Lee; Ho Nam Chang
Journal:  Curr Genet       Date:  2010-06-08       Impact factor: 3.886

4.  Regulation of epidermal Langerhans cell migration by lactoferrin.

Authors:  M Cumberbatch; R J Dearman; S Uribe-Luna; D R Headon; P P Ward; O M Conneely; I Kimber
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

5.  Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.

Authors:  P H van Berkel; H A van Veen; M E Geerts; H A de Boer; J H Nuijens
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

6.  Immunomodulatory effects of recombinant lactoferrin during MRSA infection.

Authors:  Shen-An Hwang; Marian L Kruzel; Jeffrey K Actor
Journal:  Int Immunopharmacol       Date:  2014-03-06       Impact factor: 4.932

7.  Direct activity of recombinant human lactoferrin against Helicobacter pylori.

Authors:  S Miehlke; R Reddy; M S Osato; P P Ward; O M Conneely; D Y Graham
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

8.  Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.

Authors:  Teresa G Hayes; Gerald S Falchook; Atul Varadhachary
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

9.  Cloning and expression of fungal phytases in genetically modified strains of Aspergillus awamori.

Authors:  Judith A Martin; Richard A Murphy; Ronan F G Power
Journal:  J Ind Microbiol Biotechnol       Date:  2003-08-28       Impact factor: 3.346

10.  Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses.

Authors:  Gonzalo de la Rosa; De Yang; Poonam Tewary; Atul Varadhachary; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.